A Phase 2A Safety and Biomarker Study of EPI-589 in Subjects With Amyotrophic Lateral Sclerosis
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs EPI 589 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Edison Pharmaceuticals
- 19 Apr 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
- 19 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 29 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.